What Drug Class Is Ketamine?

Ketamine sits in two separate classification systems that are easy to mix up. Pharmacologically, it's a dissociative anesthetic and an NMDA-receptor antagonist — a description of how the drug acts on the brain. Legally, it's a Schedule III controlled substance under the federal Controlled Substances Act — a description of who is allowed to prescribe, dispense, or possess it. Those two classifications answer different questions, and both explain why licensed clinics can offer ketamine treatment while buying it from anywhere else is a criminal offense.

Ketamine's Pharmacological Class: A Dissociative Anesthetic

Ketamine's own drug class is "dissociative anesthetic," a small category it shares mainly with phencyclidine (PCP) and, at high doses, dextromethorphan. How ketamine compares to PCP and other drugs comes down mostly to dose and duration — ketamine's effects resolve within an hour or two, while PCP's dissociation can last considerably longer and carries a rougher safety profile. It works by blocking NMDA receptors, a site on nerve cells that normally responds to the neurotransmitter glutamate. That blockade produces the detached, "outside your body" feeling patients report during treatment, and it's also the leading explanation for ketamine's rapid antidepressant effect. The FDA approved ketamine as a general anesthetic in 1970, and it has stayed in wide surgical and emergency use ever since.

That pharmacological class is a different family from both opioids and classic psychedelics, even though ketamine gets grouped with each in casual conversation. Opioids activate an entirely separate receptor system (mu-opioid receptors) to relieve pain and produce euphoria — a distinction covered in detail in is ketamine an opioid. Classic psychedelics like psilocybin and LSD act on serotonin receptors and typically produce vivid sensory hallucinations, which is a different experience and a different mechanism from ketamine's dissociation — the full comparison is in is ketamine a psychedelic. This article focuses on the classification question those two don't: how ketamine is regulated, and what that regulation means for how you can legally access it.

Ketamine's Legal Classification: DEA Schedule III

The Controlled Substances Act sorts drugs into five schedules based on medical use and abuse potential. Schedule I drugs, like heroin, are defined as having no accepted medical use and the highest abuse potential — they cannot be legally prescribed at all under federal law. Schedule II drugs, including oxycodone, fentanyl, and Adderall, have an accepted medical use but also a high abuse potential and a real risk of severe psychological or physical dependence, so they come with the tightest prescribing controls short of an outright ban. Schedule III sits below both of those: an accepted medical use, a moderate to low potential for physical dependence, but still enough psychological dependence potential and misuse history to require a prescription and DEA tracking.

Ketamine has been in Schedule III since 1999, placed there specifically because of its documented medical uses as an anesthetic alongside its recognized potential for recreational misuse. That places it in the same broad regulatory tier as anabolic steroids, buprenorphine, and codeine-combination products such as Tylenol with codeine — a real controlled-substance category, but a full tier below the opioids most associated with the overdose crisis and two tiers below drugs with no legal medical pathway at all.

What Schedule III Status Means in Practice

Ketamine's classification isn't just a label — it shapes how prescribing actually works. Because ketamine has an accepted medical use and sits in Schedule III, any physician with a valid DEA registration can prescribe or administer it off-label using their own clinical judgment, which is exactly why ketamine clinics have been able to offer it for depression and pain even though the FDA hasn't approved racemic ketamine for those uses. Schedule I substances don't have that option; without an accepted medical use, there's no legal prescribing pathway for them at all outside of research settings.

Schedule III also carries a lighter regulatory footprint than Schedule II. Federal rules allow Schedule III prescriptions to be authorized verbally and refilled up to five times within six months, while Schedule II prescriptions generally can't be refilled at all and often require a new written prescription for every fill. Storage and record-keeping requirements are similarly less restrictive than what applies to Schedule II opioids. None of this makes ketamine unregulated — clinics still have to register with the DEA, log dispensing, and follow their state medical board's rules, and some states layer on additional requirements of their own on top of the federal schedule. It just means the schedule itself isn't the barrier keeping most patients from accessing treatment; the FDA-approval question for a given condition is a separate matter from the scheduling question.

Esketamine vs. Racemic Ketamine: Same Schedule, Different Approval Path

Esketamine, the active ingredient in Spravato, carries the identical Schedule III status as the racemic (generic) ketamine used in IV and IM infusions. The difference between them isn't their DEA schedule — it's what happened after scheduling. Esketamine went through the full FDA New Drug Application process and won approval specifically for treatment-resistant depression and depression with suicidal thoughts. As a condition of that approval, the FDA attached a Risk Evaluation and Mitigation Strategy, or REMS, which requires Spravato to be given in a certified healthcare setting with about two hours of monitoring afterward — the patient can't take a dose home, regardless of how mild the visit feels. That restriction comes from the REMS program tied to esketamine's specific FDA approval, not from its Schedule III status; plenty of other Schedule III drugs carry no REMS requirement at all.

Racemic ketamine took a different path. It's used off-label for mental health and pain conditions, which means there's no single FDA-mandated protocol governing dose, frequency, or observation time. Individual clinics set those details based on clinical guidelines and their own prescribing physician's judgment, which is why infusion protocols and monitoring practices can vary more from one IV ketamine clinic to another than they do between two Spravato providers.

What This Means for Patients

For a patient, the practical takeaway is that legitimate access to ketamine runs through exactly two pathways, and both start with a licensed prescriber. Spravato requires evaluation by a clinician and administration at a REMS-certified pharmacy or clinic. Racemic ketamine — as an IV infusion, an intramuscular injection, or oral troches — requires a prescribing physician who has evaluated you and is willing to use it off-label, administered either in a monitored clinic setting or, for at-home protocols, dispensed through a licensed pharmacy under a physician's ongoing supervision. Before starting either, it's worth confirming the provider is who they claim to be — learn how to check a provider's credentials for the specific licenses and credentials to check.

Sourcing ketamine outside either pathway isn't just against the rules on paper — it carries real risk. Because ketamine is a Schedule III controlled substance, possessing it without a valid prescription is a federal crime on top of whatever state penalties apply, and diverted product comes with no guarantee of accurate dosing, purity, or sterility. There's also no clinician screening for contraindications like uncontrolled high blood pressure or certain psychiatric conditions, and no one monitoring you if something goes wrong during dosing — the exact function a licensed clinic exists to provide. The controlled-substance status exists because of that misuse and safety history, not as a formality, which is precisely why the legitimate pathway matters as much as the drug itself. You can browse licensed ketamine clinics by state and city to find a provider who operates within that legitimate pathway.

Frequently Asked Questions

Sources: DEA Controlled Substances Act scheduling records and public guidance, and FDA prescribing information for ketamine and esketamine (Spravato). Informational only — not medical or legal advice. Talk with a licensed clinician about your health history before starting treatment, and consult your state medical board with questions about a specific provider's licensure.